Dekkers: New Bayer Is Stable And Fit To Innovate for All Species
This article was originally published in Scrip
Executive Summary
Much of Bayer AG's third quarter earnings call fixated on the group's recent reorganization to be a "life science only" company and the competitive benefits of this decision.